Ozempic, Wegovy and Zepbound get new FDA warning over rare condition
Michelle Rivera
Michelle Rivera
Reporter · Cleveland, OH
Michelle, an Ohio State University graduate, has spent over six years focusing on community issues in Cleveland, including social justice and local initiatives. She has previously written for NPR's local affiliates, where she honed her storytelling skills to highlight diverse community voices.
More from Michelle →Reporter · Tuesday, November 10, 2026 at 2:33 PM · 1 min read
People taking popular weight-loss and diabetes drugs are getting a new safety warning. The Food and Drug Administration is requiring all GLP-1 drugs to carry information about a potential increased risk of a rare eye condition that can cause permanent vision loss, according to the FDA’s Nov. 9 drug safety communication. The medications include Ozempic, Wegovy, Mounjaro and Zepbound.